Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease
Abstract
Development of therapeutic strategies for Parkinson’s disease (PD) is hampered by the lack of reliable biomarkers to identify patients at early stages of the disease and track the therapeutic effect of potential drugs and neuroprotective agents. Readily accessible biomarkers capable of providing information about disease status are expected to accelerate this progress. We identified hepatocyte nuclear factor ( HNF4A ) and polypyrimidine tract binding protein 1 ( PTBP1 ) mRNAs as promising blood biomarkers for identifying early stage PD patients with high diagnostic accuracy. Furthermore, HNF4A was identified as a potential biomarker to monitor disease severity. Longitudinal analysis demonstrated that HNF4A and PTBP1 are longitudinally dynamic biomarkers that provide insights into the molecular mechanisms underlying the altered insulin signaling in PD patients and may enable novel therapeutic strategies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 02, 2015
- Source ID
- 10.1073/pnas.1423573112
Entities
People
- Jose A. Santiago
- Judith A Potashkin
Organizations
- National Institutes of Health
- Rosalind Franklin University of Medicine and Science
- United States Department of Defense